Introduction
The sudden 25% drop in accuracy rates for Vayyar's breast cancer screening technology during clinical trials is a critical issue that demands immediate attention. This analysis will systematically identify, validate, and address the root cause while considering both short-term and long-term implications for the product and company.
This analysis follows a structured approach covering issue identification, hypothesis generation, validation, and solution development.
Step 1
Clarifying Questions (3 minutes)
Why it matters: Software changes could directly impact accuracy rates. Expected answer: Yes, a minor update was pushed two weeks ago. Impact on approach: If confirmed, we'd focus on rollback options and code review.
Why it matters: A smaller sample size could lead to statistical anomalies. Expected answer: Sample size remained consistent at about 500 screenings per week. Impact on approach: If sample size is consistent, we'd rule out statistical variance.
Why it matters: Different demographics could affect screening accuracy. Expected answer: No significant changes in patient demographics. Impact on approach: If confirmed, we'd focus on technical or procedural issues rather than patient factors.
Why it matters: Procedural changes could affect how the technology is applied. Expected answer: No changes to protocols, but new technicians were trained recently. Impact on approach: If new technicians are involved, we'd investigate training and application consistency.
Practice similar questions
Subscribe to access the full answer